Soin Therapeutics receives FDA Orphan Drug Status Grant

Soin Therapeutics receives FDA Orphan Drug Status Grant

The US FDA (Food and Drug Administration) has granted Ohio-based pharmaceutical company Soin Therapeutics orphan drug status for low dose naltrexone (LDN) for the treatment of complex regional pain syndrome (CRPS). Complex Regional Pain Syndrome is characterized by...
Rare Disease Stakeholders Demand Regulatory Clarity

Rare Disease Stakeholders Demand Regulatory Clarity

The Food and Drug Administration (FDA) asked for rare disease stakeholders, including individuals and families affected by rare disease(s), pharmaceutical companies, trade associations, and other federal agencies and regulators, to weigh in on a proposed clinical...